What’s the best proxy for the trends that can help you make money? The answer may be the 50-day moving average, which the author of today’s article advises “is in the goldilocks zone of not being too short or too long.” Using the example of a potentially game-changing stock from the green energy sector, he outlines how traders can use…
“To me, this is the biggest contrarian bet you can make today. If you’ve got the guts to make the trade, it could lead to massive upside from here,” says the author of today’s article in regards to the investment opportunity he outlines – one that involves an investment that, being cheap, hated and in the start of an uptrend,…
While more suited for aggressive investors, and with the number of new traders skyrocketing over the past year and making good ideas to trade even harder to find, these could prove exciting additions for traders looking for solid alpha potential,” says the author of today’s article of the five Buy-rated stocks currently trading under $10 that he proceeds to highlight.…
With the daily average coronavirus cases being above 150,000 in the U.S., investors have been going back to the old playbook that worked so well last year. This could explain why the tech sector is still performing so well,” notes the author of today’s article before proceeding to highlight four tech stocks in particular to watch this week. For these…
As the biotech sector has received increased investor focus over the past year amid the COVID-19 pandemic, the author of today’s article notes that “Even the smaller and lesser known are being seen now as having immense potential; Many of these companies are working tirelessly toward new drug developments and eyeing larger collaborations.” With that, she proceeds to highlight three…
“While more suited for aggressive investors, and with the number of new traders skyrocketing over the past year and making good ideas to trade even harder to find, these could prove exciting additions for traders looking for solid alpha potential,” says the author of today’s article in regards to five Buy-rated stocks priced under $10 that he proceeds to highlight.…
Trillium Therapeutics surged 1,330% last year – and as an immuno-oncology company, its performance had nothing to do with COVID-19 related catalysts. Moreover, its 2020 run may have just been the beginning, as the company’s cancer-fighting candidates – which it hopes will ultimately replace chemotherapy as the dominant type of cancer treatment – are, as today’s article explains, currently in…
“These four look like solid picks for more aggressive growth investors as they have significant catalysts that can drive growth for the rest of 2021 and beyond,” says the author of today’s article in regards to the four stocks he proceeds to highlight, each of which is a top growth stock call for 2021 from Jefferies. For these four stocks…
One of the strongest biotechs out there, a diamond in the rough, and a high-risk, high-reward play make up the three biotech stocks identified by the author of today’s article as top picks for 2021 for investors looking for even better biotech returns than those offered by broad biotech ETFs such as the SPDR S&P Biotech ETF. For a look…
While biotech stocks have been hot over the last year, today’s article notes that another group of stocks have been trading like biotech companies of late: psychedelic stocks. In fact, a slew of psychedelic stocks have posted triple-digit returns over the last year – and with the impending release of studies examining the use of psychedelics to treat mental health…